Australia markets closed

GSK plc (GSK.L)

LSE - LSE Delayed price. Currency in GBp (0.01 GBP)
Add to watchlist
1,586.00-4.00 (-0.25%)
As of 12:17PM BST. Market open.
Full screen
Previous close1,590.00
Bid1,586.00 x 0
Ask1,586.50 x 0
Day's range1,584.50 - 1,600.24
52-week range1,302.60 - 1,725.81
Avg. volume9,185,474
Market cap64.805B
Beta (5Y monthly)0.27
PE ratio (TTM)13.22
EPS (TTM)1.20
Earnings date01 May 2024
Forward dividend & yield0.64 (4.03%)
Ex-dividend date22 Feb 2024
1y target estN/A
  • Insider Monkey

    10 Best Weight Loss Drug Stocks to Buy Now

    In this piece, we will take a look at the ten best weight loss drug stocks to buy now. If you want to skip our introduction to the rising weight loss drug industry and how it’s one of the biggest trends on the stock market right now, then you can take a look at the […]

  • Zacks

    GSK PLC Sponsored ADR (GSK) is Attracting Investor Attention: Here is What You Should Know

    Recently, users have been paying close attention to Glaxo (GSK). This makes it worthwhile to examine what the stock has in store.

  • Reuters

    UPDATE 1-U.S. FDA approves Akebia's anemia drug

    The U.S. Food and Drug Administration approved Akebia Therapeutics' drug, vadadustat, to treat anemia caused by chronic kidney disease (CKD) in dialysis patients, the drugmaker said on Wednesday. The FDA had earlier declined to approve vadadustat - a Hypoxia-inducible factor–prolyl hydroxylase (HIF-PH) inhibitor - on safety concerns, as it posed an increased risk of blood clot formations and drug-induced injuries to the liver.